title: The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
abstract: OBJECTIVE
  The epidemiology and treatment of prostate cancer have changed dramatically in the prostate specific antigen era. A large disease registry facilitates the longitudinal observation of trends in disease presentation, management and outcomes.
  
  
  METHODS
  The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national disease registry of more than 10000 men with prostate cancer accrued at 31 primarily community based sites across the United States. Demographic, clinical, quality of life and resource use variables are collected on each patient. We reviewed key findings from the data base in the last 8 years in the areas of disease management trends, and oncological and quality of life outcomes.
  
  
  RESULTS
  Prostate cancer is increasingly diagnosed with low risk clinical characteristics. With time patients have become less likely to receive pretreatment imaging tests, less likely to pursue watchful waiting and more likely to receive brachytherapy or hormonal therapy. Relatively few patients treated with radical prostatectomy in the database are under graded or under staged before surgery, whereas the surgical margin rate is comparable to that in academic series. CaPSURE data confirm the usefulness of percent positive biopsies in risk assessment and they have further been used to validate multiple preoperative nomograms. CaPSURE results strongly affirm the necessity of patient reported quality of life assessment. Multiple studies have compared the quality of life impact of various treatment options, particularly in terms of urinary and sexual function, and bother.
  
  
  CONCLUSIONS
  The presentation and management of prostate cancer have changed substantially in the last decade. CaPSURE will continue to track these trends as well as oncological and quality of life outcomes, and will continue to be an invaluable resource for the study of prostate cancer at the national level.
authors.affiliation: Department of Urology, University of California-San Francisco/Mt Zion Comprehensive Cancer Center, San Francisco, California 94115-1711, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Cooperberg
authors.forename: Jeanette M
authors.initials: JM
authors.lastname: Broering
authors.forename: Mark S
authors.initials: MS
authors.lastname: Litwin
authors.forename: Deborah P
authors.initials: DP
authors.lastname: Lubeck
authors.forename: Shilpa S
authors.initials: SS
authors.lastname: Mehta
authors.forename: James M
authors.initials: JM
authors.lastname: Henning
authors.forename: Peter R
authors.initials: PR
authors.lastname: Carroll
mesh_terms: D035843:Biomedical Research / Q000458:organization & administration*; D016208:Databases, Factual; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians'; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D016896:Treatment Outcome; D014481:United States